Zoetis (ZTS)

Healthcare · Drug Manufacturers - Specialty & Generic · S&P 500
$71.33 -0.11% on the day Market cap $31.7B 52-week range $68.77 to $148.30 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
0% a year for 10 years

At a market value of $31.7B, Zoetis's free cash flow of $2.3B (fiscal 2025) would need to grow about 0% a year for the stock to be worth today's price. That is slower than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Zoetis's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price0.2% a year
Free cash flow, last 9 years18.5% a year
Revenue, same period7.6% a year
Price to free cash flow13.9x

Fundamental grade

B

Five factors scored 1 to 9 from ZTS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation6
Profitability9
Growth2
Financial health5
Cash efficiency9

Key numbers

P/E (trailing)12.4x
P/E (forward)10.7x
Price / free cash flow13.9x
EV / EBITDA9.65x
Price / sales3.34x
Price / book9.67x
Revenue growth+0.3%
Operating margin—
Net margin27.5%
Return on equity83.1%
Dividend yield2.7%
Debt / equity3.79x

Results from SEC filings

Fiscal years, from Zoetis's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$7.8B$8.1B$8.5B$9.3B$9.5B
Net income$2.0B$2.1B$2.3B$2.5B$2.7B
Free cash flow$1.7B$1.3B$1.6B$2.3B$2.3B
EPS (diluted)$4.27$4.49$5.07$5.47$6.02
Operating margin—————

Where the revenue comes from

Revenue by products, fiscal 2025.

Companion Animal$6.6B70%
Livestock$2.8B29%
Contract Manufacturing and Human Health Diagnostics$116M1%

Superinvestors who own ZTS

From each investor's latest 13F filing (what a 13F shows). 9 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Ric Dillon
Diamond Hill Capital Management
Added $256M2.0%Q2 2026
Ruane, Cunniff & Goldfarb
Ruane, Cunniff & Goldfarb
Trimmed $169M2.6%Q2 2026
Charles Brandes
Brandes Investment Partners, LP
New position $139M0.97%Q2 2026
Bill Smead
Smead Capital Management
New position $89M1.9%Q2 2026
Cliff Asness
AQR Capital Management
Added $77M0.03%Q2 2026
Tweedy, Browne
Tweedy, Browne Company
New position $40M3.0%Q2 2026
Joel Greenblatt
Gotham Asset Management
Added $38M0.09%Q2 2026
Tom Gayner
Markel Group Inc.
New position $5M0.04%Q2 2026
Mario Gabelli
GAMCO Investors
Trimmed $891,9980.01%Q2 2026

Insider buying

Open-market purchases by Zoetis's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Feb 10, 2026 Gilbert Ray Cisneros, Jr.
0$128.13—
Feb 10, 2026 Gilbert Ray Cisneros, Jr.
0$128.13—
Jan 13, 2026 Ro Khanna
0$124.60—
Jan 13, 2026 Ro Khanna
0$124.60—
Jan 6, 2026 Ro Khanna
0$129.32—
Jan 6, 2026 Ro Khanna
0$129.32—
Dec 19, 2025 Gilbert Ray Cisneros, Jr.
0$122.34—
Dec 19, 2025 Gilbert Ray Cisneros, Jr.
0$122.34—
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$118.30—
Nov 18, 2025 Gilbert Ray Cisneros, Jr.
0$118.30—

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when ZTS trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Zoetis's stock price imply?

At a market value of $31.7B, Zoetis would need its free cash flow to grow about 0% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew 18% a year.

Are Zoetis insiders buying the stock?

10 open-market insider purchases of ZTS in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Zoetis?

9 of the superinvestors Investingly tracks hold ZTS in their latest 13F, including Ric Dillon, Ruane, Cunniff & Goldfarb, Charles Brandes.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.